Hers vs Ivim Health: Care Model and GLP-1 Compared

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Welcome to the PlexusDx Education Hub, where we translate GLP-1 science, weight-management options, and the genetics beneath them into decisions you can actually use. Explore the full Peptides & GLP-1 library.

The following is independent editorial analysis. PlexusDx has no affiliate, sponsorship, or commercial relationship with Hers, Ivim Health, or their parent companies.

A Hers versus Ivim Health comparison is best read through the lens of care model: how clinical oversight, provider access, and the compounding pathway are organized around the same drug class. This page emphasizes the structure of care at each program, then the shared pharmacology and the genetic context both leave out. Market context reflects April 2026.

How care is organized at each program

Hers (Hims & Hers Health) runs subscription telehealth: a virtual clinical evaluation, provider-issued prescriptions, and either brand-name FDA-approved dispensing or compounded semaglutide or tirzepatide via a licensed compounding pharmacy. Ivim Health pairs telehealth with a compounding-pharmacy pathway. Both place a licensed provider between you and the prescription, but the cadence of follow-up, the type of provider interaction, and the ongoing support differ, and those details define the day-to-day care experience.

The compounding pathway and oversight

When either program dispenses compounded semaglutide or tirzepatide, it works through a 503A compounding pharmacy under provider supervision. That pathway is a legitimate, regulated route, and the oversight around it, prescription, follow-up, and dose adjustments, is part of what you are paying for. Comparing Hers and Ivim on care means asking how accessible providers are and how actively each manages the ongoing prescription, not just what the medication costs.

The pharmacology under the care model

The care wrapper does not change the compound. GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, and the GIP/GLP-1 dual agonist tirzepatide, act on appetite regulation, satiety, and gastric emptying. A more attentive care model can improve your experience and adherence, but the underlying mechanism is a property of the molecule, identical whether Hers or Ivim manages your prescription.

What the trials showed

The evidence belongs to the compounds, regardless of care model. Semaglutide for weight management was studied in STEP (NEJM 2021), tirzepatide in SURMOUNT (NEJM 2022), and tirzepatide for obstructive sleep apnea in SURMOUNT-OSA (NEJM 2024). Effect sizes depend on dose, compound, and population. No care structure adds to or subtracts from this clinical record.

The context no care model captures

Even attentive oversight cannot see your genetics. A variant in TCF7L2, linked to glucose homeostasis and GLP-1 secretion, or in FTO, GLP1R, and MC4R, describes the metabolic terrain a GLP-1 compound acts on. These markers are pathway-level and do not predict response to any specific medication. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including TCF7L2, FTO, MC4R. Paired with the PlexusDx Weight Management Protocols, offered at $189 for Semaglutide Injection and $289 for Tirzepatide Injection month to month, it is the test before you invest approach that gives any care team upstream biology to work with.

No affiliation: PlexusDx has no commercial relationship with Hers or Ivim Health and does not represent either company.

More from the Education Hub: GLP 1 What Is and GLP 1 Drugs.

Disclaimer: This comparison is educational. PlexusDx is not affiliated with Hers or Ivim Health. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Frequently Asked Questions

How do Hers and Ivim Health differ on care?

Both place a licensed provider between you and the prescription, but they organize follow-up, provider access, and ongoing support differently. Hers is subscription telehealth; Ivim pairs telehealth with a compounding-pharmacy pathway. The care experience, how actively each manages your prescription, is where the meaningful differences tend to appear.

Is compounded medication safe under these programs?

Compounded semaglutide or tirzepatide is prepared by a licensed 503A compounding pharmacy under provider supervision, a legitimate regulated route. Both Hers and Ivim may use it. As with any medication decision, discuss the specific product, dose, and monitoring with the prescribing provider before starting or changing a protocol.

Does the Precision Peptide Genetic Test replace clinical oversight?

No. It complements it. The test maps pathway-level variants such as TCF7L2, FTO that describe your baseline GLP-1 biology. It does not predict medication response or substitute for a provider; it gives your care team upstream genetic context to weigh alongside their clinical judgment.

Keep learning at the PlexusDx Education Hub. Return to the Peptides & GLP-1 library.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.